Belgium, Prior investment

Pharma Diagnostics develops a unique drug discovery screening technology based on localised surface plasmon resonance and noble metal nanoparticles in solution. The platform is high throughput, highly sensitive, label-free and requires no specialist instrumentation.  It is particularly relevant to fragment screening and antibody screening.

Responsible: Marc Wachsmuth

News about
Ulf Jönsson, former CEO of Biacore, joins PharmaDiagnostics as non-executive Director

Overview portfolio